News und Analysen
Sensorion to Host Key Opinion Leader Webinar on July 5, 2023; Confirms Upcoming Key Milestones
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Vistagen Announces Stockholder-Approved Reverse Stock Split
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented a poster and a publication in abstract book featuring Tedopi®, an immunotherapy activating tumor specific
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders
EQS-News: Heidelberg Pharma reports on the results of the Annual General Meeting 2023
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces today the results of
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Valbiotis meldet durchschlagenden Erfolg der internationalen multizentrischen Phase-II/III-Studie REVERSE-IT zu TOTUM•63: nachgewiesene Wirksamkeit bei Hauptrisikofaktor für Typ-2-Diabetes
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/PME-fähig) (Paris:ALVAL), ein kommerziell ausgerichtetes Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen
Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and
Newron Presents Exciting New Data From Study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
Sensorion Will Present Two Posters At The American Society Of Cell And Gene Therapy (ASGCT) 26th Annual Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its participation in
EQS-News: Heidelberg Pharma appoints Chief Financial Officer
Newron to Present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented two additional posters reporting the latest research updates on CLEC-1 (new myeloid immune checkpoint), from
Newron Announces Senior Management Team Changes
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Sensorion to Host a Symposium during ISIET’s International Symposium on Inner Ear Therapeutics on April 30, 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce it will host a
OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces three presentations at the American Association for Cancer Research (AACR) Annual Meeting in Orlando
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 24, 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company’s
OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2022 and provided an update on key clinical and